Health

Dr. Bryan Ardis: There is a COVID-19 Medication That is CHEAP, EFFECTIVE, and APPROVED

Dr. Bryan Ardis informs his audience that the National Institutes of Health (NIH) has approved ivermectin as a treatment for a Wuhan coronavirus (COVID-19) infection.

Ivermectin is listed as one of three medications in a chart headed “Characteristics of Antiviral Agents that are Approved or Under Evaluation for the Treatment of COVID-19” on the NIH website, according to Ardis. Remdesivir and nitazoxanide are the other medications on the list.

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

“It’s an enormously significant graph. “Everyone needs it,” Ardis says on Brighteon.The TV’s Dr. Ardis Show.

If you have a loved one in a hospital with COVID-19, Ardis advises you can take a copy of their chart and show the doctors that ivermectin is an approved treatment for the disease. “You will save your loved ones’ lives and you will be able to hold hospitals accountable for the doses — doctors can’t say you they don’t know how to use that drug; the NIH informs you how to use that drug,” Ardis explains.

That chart could have spared the life of Veronica Wolski, a well-known Chicago patriot who died at AMITA Health Resurrection Medical Center from COVID-19. Wolski had been requesting ivermectin from the hospital, according to her friend Nancy Ross, but her pleas had been consistently denied.

Remdesivir is an antiviral drug that works against a variety of viruses. Coronaviruses contain ribonucleic acid-based genomes (RNA). Remdesivir prevents the virus from reproducing by interfering with one of the essential enzymes required for RNA replication.

Many patients who got remdesivir, on the other hand, had multiple organ failure and/or acute kidney failure as a result of the drug. The NIH chart contains a list of those serious side effects.

Ardis provides another document that explains why hospitals choose to use remdesivir to treat COVID-19 patients. The Centers for Medicare & Medicaid Services (CMS) website has a chart titled New COVID-19 Treatments Add-On Payment (NCTAP).

The Medicare program offers an additional reimbursement for qualifying inpatient cases that use specific new medications with current FDA approval or emergency use permission to treat COVID-19 through the NCTAP. Remdesivir is the sole medicine that fits within this category.

This additional payment refers to a 20% incentive paid to hospitals for treating all COVID-19 patients with remdesivir rather than any other medicine.

“They’re bribing hospitals and doctors to choose remdesivir,” adds Ardis, noting that the CMS is presently paying $2,400 for a five-day remdesivir therapy. In other words, hospitals are earning an extra $480 for each patient.

Ivermectin costs less than $2 per tablet as a comparison.

For the uninitiated, remdesivir is the sole FDA-approved medication for the condition. It’s safe to use in adults and children over the age of 12 who weigh at least 88 pounds (40 kilograms).

Ivermectin has been demonstrated to be both safe and effective.
Despite severe side effects, bribery, and a significant price differential, Ardis claims that remdesivir is not as effective as ivermectin in treating COVID-19 patients. “Ivermectin has been shown to be both safe and effective. Nobody has ever died from it, and it has never caused acute renal failure. This is a widely prescribed medication.”

Ivermectin drastically reduced COVID-19 infections in Delhi, India, according to the Desert Review, which has a population of over 30 million people.

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

On April 20, Delhi’s health authorities began administering ivermectin to patients. It was dealing with almost 30,000 new cases every day at the time. COVID-19 instances in the metropolitan area had dropped to less than 1,000 new cases per day by the end of May. (Related: In Delhi, India, widespread ivermectin use has resulted in a 97 percent reduction in coronavirus cases.)

WHO is not a fan of Remdesivir.

In the meanwhile, the World Health Organization (WHO) has issued a conditional recommendation against using remdesivir in hospitalized patients, regardless of disease severity, because there is no evidence that it improves patient survival or other outcomes.

The suggestion is part of a living clinical care guideline for COVID-19. An international guideline development panel comprised of 28 clinical care specialists, four patient partners, and one ethicist established it.

Remdesivir is less effective than budesonide.
In comparison to remdesivir, budesonide is a more successful and less hazardous treatment for COVID-19.

Early therapy with inhaled budesonide reduced the requirement for urgent care and hospitalization in persons with COVID-19 by up to 90%, according to researchers at the University of Oxford. The study also discovered that giving COVID-19 patients inhalation budesonide after seven days of onset of symptoms lowers recovery duration.

After 28 days, participants who were given the budesonide inhaler had a faster clearance of fever, symptoms, and less persisting symptoms. In addition, individuals who got budesonide had fewer lasting symptoms, according to the study.

Budesonide has been prescribed by doctors as an asthma preventative drug for more than 20 years. Dr. Richard Bartlett, a staunch supporter of the medicine, has authored a paper containing case reports indicating positive results for two of his patients who were given the treatment. Budesonide also decreased the ability of a coronavirus to reproduce and inflame the airways, according to a lab study conducted in the United States.

The Dr. Ardis Show episode from September 29 can be seen here:

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

Source
www.onenewspage.comwww.play.anghami.com www.naturalnews.com

Margaret Taylor

Experienced communications professional with 10 years of experience in international journalism.

Related Articles

Back to top button

Adblock Detected

For continue reading on the site please disable the Ad-block